| Dr John Patrick Moore, DDS | |
|
865 Oilfield Ave, Shelby, MT 59474-2702 | |
| (406) 434-5146 | |
| (406) 434-5147 |
| Full Name | Dr John Patrick Moore |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 865 Oilfield Ave, Shelby, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083777684 | NPI | - | NPPES |
| 139113 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 1494 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Patrick Moore, DDS 865 Oilfield Ave, Shelby, MT 59474-2702 Ph: (406) 434-5146 | Dr John Patrick Moore, DDS 865 Oilfield Ave, Shelby, MT 59474-2702 Ph: (406) 434-5146 |
News Archive
A new investigational drug designed to stop cancer cells from reproducing may offer hope for patients with advanced solid tumor cancers. Clinical trials of TKM-PLK1 for qualified patients are now open at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.
A new study revealed that people with diabetes may be at an increased risk of developing dementia. Scientists have suspected the link between the two diseases for several years, but several experts say this latest study highlights how treating preventable diseases like diabetes and obesity may be useful in preventing the onset of dementia.
Convergent Dental, Inc., a privately held dental device and technology company, announced today that the U.S. Food and Drug Administration (FDA) has cleared Solea™ for ablation of hard tissue for caries removal and cavity preparation. Solea is the first CO2 laser technology system that has received FDA clearance for hard tissue indications.
University of Michigan researchers have discovered a new cause of congenital myopathy: a mutation in a previously uncharacterized gene, according to research published this month in the American Journal of Human Genetics.
Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center
› Verified 3 days ago
Dylan E Weishaar, DDS Dentist Medicare: Medicare Enrolled Practice Location: 865 Oilfield Ave, Shelby, MT 59474 Phone: 406-434-3142 Fax: 406-434-3143 | |
Dr. Bryan Drew Haight, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 865 Oilfield Ave, Suite 3, Shelby, MT 59474 Phone: 406-434-7086 | |
Dr. Scott Allen Luly, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 50 Crossroads Drive, Shelby, MT 59474 Phone: 406-470-4111 | |
Gregory Trandon Lee Jefferson, Dentist Medicare: Not Enrolled in Medicare Practice Location: 865 Oilfield Ave, Shelby, MT 59474 Phone: 406-434-3142 |